Department of Biometrics Research
Merck Research Laboratories
Dr. Xiaohua Douglas Zhang is an Associate Director, Scientific Staff, in Merck Research Laboratories. He got his Ph.D. in statistics from Carnegie-Mellon University, PA, USA, an MS in Genetics and a BS in Biology from Beijing Normal University, China. He has worked on analyzing data generated from new biotechnologies. He has analyzed many high-throughput screening (HTS) projects for many years. Merck has put great effort into RNAi research. It purchased Sirna for $1.1 billion in 2006 and has one of the largest labs for conducting RNAi/compound HTS. Since early 2005, Dr. Zhang has led data analysis in RNAi HTS projects at Merck and has continuously developed and adopted experimental designs and analytic methods for HTS projects including novel analytic methods for quality controls and hit selection, which allows him and his colleagues to continuously publish papers in the HTS area. He has a book titled "Optimal High-Throughput Screening: Practical Experimental Design and Data Analysis for Genome-scale RNAi Research" published by Cambridge University Press in 2011. He has organized/chaired many sessions in professional meetings, has reviewed grant proposals for NIH and European Commission, and has refereed many manuscripts submitted to prestigious journals such as Nature, Nature Methods, Journal of American Statistical Association, Bioinformatics, etc.